Breaking Research Could Reduce Healthcare Disparities by Making Kidney Disease Diagnosis and Treatment More Equitable

New Findings to Be Highlighted at the 2022 AACC Annual Scientific Meeting

CHICAGO, July 26, 2022 /PRNewswire/ -- New research shows that removing a race modifier from a formula used to diagnose kidney disease could lead to more equitable care for Black patients. This study and a second that examines how this same diagnostic approach impacts Asian patients will be presented at the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo.

One of the standard ways to diagnose kidney disease is by estimating glomerular filtration rate (eGFR) with a mathematical formula. Race has long been used as a variable in eGFR equations because researchers and clinicians mistakenly believed that Black people have higher muscle mass and/or creatinine metabolism than White people. The formula most widely used to determine eGFR, the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI), includes variables for serum creatinine, gender, race, and age. However, the National Kidney Foundation and the American Society of Nephrology now recommend that clinical laboratories use a revised CKD-EPI refit formula developed in 2021 for assessing kidney function that does not include a race modifier. Two studies discussed at 2022 AACC set out to determine how effective this new formula is.

Impact of Removing Race Adjustment on Chronic Kidney Disease Staging
Researchers at the University of Texas (UT) Southwestern Medical Center and Parkland Health, Dallas, led by Ibrahim Hashim, PhD, examined serum creatinine values of 56,676 patients over a 16-month timeframe and estimated eGFR using the previous CKD-EPI formula and the new CKD-EPI refit formula. After removing the race adjustment, 14% to 28% of Black patients were reclassified into a more severe chronic kidney disease stage.

Based on these results, the researchers support removing race as a factor in eGFR equations, noting that it perpetuates systemic racism and discrimination in healthcare, and that its removal will provide more equitable care and reduce healthcare disparities. UT Southwestern began using the new formula in May, noted Hashim.

"Race is a social construct," he said. "By removing race as a variable, patients are now objectively classified, which opens access for additional testing and more investigation into their condition. This can only lead to better care for patients with chronic kidney disease. This is very significant because we know there is racial disparity in healthcare. By removing race as a factor, medicine becomes more personalized."

Accuracy of the New eGFR Equation in Korea
Researchers at several different medical schools and hospitals in Korea also assessed the new 2021 CKD-EPI equation in a Korean population, as very few studies have evaluated the new equation's performance in Asian patients. The researchers compared eGFR results from 1,899 people with results from chromium-51-ethylenediamine tetraacetic acid GFR measurements (the gold standard for determining GFR). Interestingly, they found that the mean bias of the 2021 CKD-EPI refit formula was significantly greater than that of the original CKD-EPI formula when comparing test results for both males and females.

This means that "additional research is needed to decide whether to apply the 2021 CKD-EPI equation in clinical practice" with Asian patients, said Tae-Dong Jeong, MD, PhD, the lead author of the study and a researcher with Ewha Womans University College of Medicine in Seoul.

Abstract Information

AACC Annual Scientific Meeting registration is free for members of the media. Reporters can register online here: https://www.xpressreg.net/register/aacc0722/media/landing.asp

A-029 Impact of removing race adjustment when estimating GFR on chronic kidney disease staging and

A-109 Accuracy of the new creatinine based equation to estimate glomerular filtration rate without race in Korea will be presented during:

Scientific Poster Session
Tuesday, July 26
9:30 a.m. – 5 p.m. (presenting author in attendance from 1:30 – 2:30 p.m.)
Poster Hall, Clinical Lab Expo show floor
McCormick Place Convention Center
Chicago

About the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo

The AACC Annual Scientific Meeting offers 5 days packed with opportunities to learn about exciting science from July 24-28. Plenary sessions will explore artificial intelligence-based clinical prediction models, advances in multiplex technologies, human brain organogenesis, building trust between the public and healthcare experts, and direct mass spectrometry techniques.

At the AACC Clinical Lab Expo, more than 750 exhibitors will fill the show floor of the McCormick Place Convention Center in Chicago with displays of the latest diagnostic technology, including but not limited to COVID-19 testing, artificial intelligence, mobile health, molecular diagnostics, mass spectrometry, point-of-care, and automation.

About AACC
Dedicated to achieving better health through laboratory medicine, AACC brings together more than 70,000 clinical laboratory professionals, physicians, research scientists, and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of progressing laboratory science. Since 1948, AACC has worked to advance the common interests of the field, providing programs that advance scientific collaboration, knowledge, expertise, and innovation. For more information, visit www.aacc.org.

Christine DeLong
AACC
Senior Manager, Communications & PR
(p) 202.835.8722
[email protected]

Molly Polen
AACC
Senior Director, Communications & PR
(p) 202.420.7612
(c) 703.598.0472
[email protected] 

SOURCE AACC

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED